A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms AESOP
  • Sponsors Intercept Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2017 Results will be presented at The Liver Meeting 2017, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
    • 31 Jul 2017 Results published in a Intercept Pharmaceuticals media release.
    • 31 Jul 2017 Primary endpoint of (Evaluate the effects of obeticholic acid (OCA) on serum alkaline phosphatase (ALP) subjects with Primary Sclerosing Cholangitis (PSC)) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top